AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock

$10.39

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/4/2025

About Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.

Website: https://www.amneal.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1723128
Address
,
Valuation
Market Cap
$3.43B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
86.10
Performance
EPS
$-0.38
Dividend Yield
Profit Margin
-4.18%
ROE
-881.00%
Technicals
50D MA
$8.15
200D MA
$8.14
52W High
$9.47
52W Low
$5.18
Fundamentals
Shares Outstanding
313M
Target Price
$11.67
Beta
1.07

AMRX EPS Estimates vs Actual

Estimated
Actual

AMRX News & Sentiment

Oct 03, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Oct 02, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Sep 30, 2025 • Benzinga NEUTRAL
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) ( "Amneal" or the "Company" ) , a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to ...
Sep 26, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® ( omalizumab )
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for ...
Sep 04, 2025 • Benzinga NEUTRAL
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Another addition to Amneal's growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced the U.S.
Sep 01, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts Think Amneal ( AMRX ) Could Surge 25.52%: Read This Before Placing a Bet
The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sentiment Snapshot

Average Sentiment Score:

0.243
50 articles with scored sentiment

Overall Sentiment:

Bullish

AMRX Reported Earnings

Mar 31, 2025
Mar 31, 2025 (Pre market)
0.06 Surprise
  • Reported EPS: $0.21
  • Estimate: $0.15
  • Whisper:
  • Surprise %: 43.1%
Dec 31, 2024
Dec 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.15
  • Whisper:
  • Surprise %: -21.1%
Nov 08, 2024
Sep 30, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $0.16
  • Estimate: $0.13
  • Whisper:
  • Surprise %: 23.1%
Aug 09, 2024
Jun 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $0.16
  • Estimate: $0.14
  • Whisper:
  • Surprise %: 14.3%
May 03, 2024
Mar 31, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.09
  • Whisper:
  • Surprise %: 55.6%
Mar 01, 2024
Dec 31, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.09
  • Whisper:
  • Surprise %: 55.6%
Nov 07, 2023
Sep 30, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.13
  • Whisper:
  • Surprise %: 46.1%
Aug 04, 2023
Jun 30, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.11
  • Whisper:
  • Surprise %: 72.7%
May 05, 2023
Mar 31, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.10
  • Whisper:
  • Surprise %: 20.0%

Financials